PTC Therapeutics came into this Q3 2026 earnings print with a reputation as a high risk rare disease story that could one day justify its valuation through blockbuster genetics. The stock had already ...
Source LinkPTC Therapeutics came into this Q3 2026 earnings print with a reputation as a high risk rare disease story that could one day justify its valuation through blockbuster genetics. The stock had already ...
Source Link
Comments